Compare · NXGL vs WST
NXGL vs WST
Side-by-side comparison of NexGel Inc (NXGL) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NXGL and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST is the larger of the two at $26.96B, about 10676.9x NXGL ($2.5M).
- NXGL has been more active in the news (5 items in the past 4 weeks vs 4 for WST).
- WST has more recent analyst coverage (20 ratings vs 2 for NXGL).
- Company
- NexGel Inc
- West Pharmaceutical Services Inc.
- Price
- -
- -
- Market cap
- $2.5M
- $26.96B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 5
- 4
- Recent ratings
- 2
- 20
NexGel Inc
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was founded in 1997 and is based in Langhorne, Pennsylvania.
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest NXGL
- NEXGEL Announces 1-for-20 Reverse Stock Split Effectiveness
- SEC Form 8-K filed by NexGel Inc
- NexGel Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- NexGel Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- NEXGEL Announces Dial-In Details for Investor Update Call
- NEXGEL Announces Date for Investor Update Call
- SEC Form DEF 14A filed by NexGel Inc
- NexGel downgraded by Maxim Group
- NexGel Inc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- NEXGEL ANNOUNCES LEADERSHIP TRANSITION AND STRATEGIC REVIEW INITIATIVE
Latest WST
- West to Host Third-Quarter 2026 Conference Call
- West to Highlight Industry Leadership in Packaging and Containment at CPHI Worldwide
- SEC Form 4 filed by Director Haugen Janet Brutschea
- West Pharm upgraded by Morgan Stanley with a new price target
- Sr. VP & Chief HR Officer Favorite Annette F exercised 7,524 shares at a strike of $89.64 and sold $2,671,260 worth of shares (7,524 units at $355.03) (SEC Form 4)
- Sr. VP & Chief HR Officer Favorite Annette F exercised 8,135 shares at a strike of $85.37 and sold $2,772,489 worth of shares (8,135 units at $340.81) (SEC Form 4)
- SEC Form 4 filed by President and CEO Lagarde Michel
- New insider Lagarde Michel claimed ownership of 7,850 shares (SEC Form 3)
- UBS resumed coverage on West Pharm with a new price target
- West to Participate in Upcoming Investor Conferences